Načítá se...
A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal(®) Dispersion (NCD) in Patients with Taxane-Refractory, Metastatic Castrate-Resistant Prostate Cancer (CRPC)
PURPOSE: 2ME2 (Panzem(®)) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC. EXPERIMENTAL DE...
Uloženo v:
Hlavní autoři: | , , , , , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
2010
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3042040/ https://ncbi.nlm.nih.gov/pubmed/20499131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9455-x |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|